Nansha cell, gene industry makes therapy breakthroughs

The China Nansha Cell and Gene Industry Innovation and Development Conference was held on Aug 26 at the Guangzhou Nansha International Convention and Exhibition Center, showcasing Nansha's achievements in the cell and gene industry and exploring how Nansha can overcome bottlenecks to become a global hub for treatments.

Linnan Technology in Nansha district has made a critical breakthrough in the treatment of β-thalassemia by genetically modifying patients' autologous hematopoietic stem cells, achieving a curative therapy. So far, 14 patients have received treatment, with nine of them recovering and being discharged.

Cell Gene Biotech Nansha district has introduced a new treatment option for patients with liver failure by developing a bone marrow mesenchymal stem cell injection, the first related drug in China to enter clinical trials, which offers an increased survival rate for patients with acute-on-chronic liver failure. Four patients have received treatment, with one already discharged.

Cell Gene Biotech also plans to establish a production branch in Nansha and advance clinical applications for other indications.

The efforts of these innovative companies have laid the foundation for Nansha's rise in the global cell and gene therapy field.

Guangzhou Nansha International Convention and Exhibition Center. [Photo/WeChat account: gz_nanshafabu]